Richard J. Nowak, MD, is director of the Myasthenia Gravis Clinic, director of Clinical & Translational Neuromuscular Research (CTNR), and associate professor of neurology at Yale School of Medicine.

The treatment pipeline for generalized myasthenia gravis (gMG) continues to be active, a consequence of the ongoing progress in knowledge that led to approval of six new drugs for the disease. In ...

Myasthenia gravis is a rare disease where the immune system attacks the communication between nerves and muscles, causing weakness. It often affects the muscles used for eye movement, facial ...

NEW HAVEN, Conn. (WTNH) — In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and what treatments are available? Dr. Kunal Desai, ...

The US Food and Drug Administration (FDA) has approved nipocalimab-aahu (Imaavy, Johnson & Johnson) for the treatment of generalized myasthenia gravis (gMG) in adults and adolescents 12 years of age ...

Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad population of antibody positive ...

New guidelines and advocacy enhance myasthenia gravis treatment access, promoting proactive management and improved insurance coverage for diverse patient populations. There are key systemic factors ...

Orphan designation was granted in 2022 by the European Commission to zilucoplan for the treatment of myasthenia gravis. 2 gMG is a chronic and unpredictable auto-immune disease in which pathogenic ...

It's important to enhance MG treatment outcomes with strong provider-patient relationships and ongoing monitoring, explain Ratna Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD. There is a critical need ...

A new study looked at mortality trends in the U.S. among more than 37,000 individuals with MG over a 23-year period. Age-adjusted mortality rates in MG increased significantly over the study period, ...